🔴 BreakingDrug approvalEMAYesterday
The European Medicines Agency has approved a new medicine called Jascayd (nerandomilast) to treat adults with two types of lung scarring diseases: idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. This approval means the medicine is now available for patients in the European Union. This is the first time this particular medicine has been approved for these conditions in Europe.
WHY IT MATTERSPatients with idiopathic pulmonary fibrosis in the EU now have access to a newly approved treatment option that may help slow lung scarring and preserve breathing ability.
Drug approvalEMAYesterday
The European Medicines Agency approved eight new medicines in May 2026. The article mentions a few specific drugs, including Jascayd (nerandomilast) and Boey (trenibotulinumtoxinE), though details about what diseases they treat are incomplete in this announcement.
WHY IT MATTERSIf you have a rare disease, one of these eight newly approved medicines might be a treatment option available in Europe — check with your doctor to see if any match your condition.
🔴 BreakingDrug approvalEMAMay 11
The European Medicines Agency has approved a new medicine called Redemplo (plozasiran) for adults with familial chylomicronaemia syndrome (FCS), a rare genetic condition where the body cannot properly break down certain fats in the blood. This medicine helps reduce triglycerides, which are a type of fat that builds up to dangerous levels in people with FCS. The approval means the medicine is now available for patients in the European Union.
WHY IT MATTERSAdults with FCS in the EU now have access to a new treatment option that specifically targets triglyceride reduction, potentially reducing their risk of severe pancreatitis and other complications from extremely high blood fat levels.
Drug approvalEMAMay 11
The European Medicines Agency has approved a new vaccine for cats called Nobivac NXT HCPChFeLV that uses RNA technology to protect against common cat diseases. This is the first veterinary vaccine using this newer RNA technology approach. The vaccine can now be sold and used in European Union countries.
WHY IT MATTERSWhile this veterinary vaccine approval doesn't directly treat human rare diseases, it demonstrates that RNA vaccine technology is advancing and becoming safer—knowledge that may eventually benefit human patients with rare genetic diseases through similar vaccine or gene therapy approaches.
Drug approvalEMAMay 11
The European Medicines Agency's committee met in April 2026 and recommended five new medicines for approval in Europe. One of these medicines is called Cenrifki (tolebrutinib), though the article doesn't provide complete details about what diseases these medicines treat. This is a routine announcement about medicines moving forward in the approval process.
WHY IT MATTERSIf you or a loved one has a condition treated by one of these five newly recommended medicines, approval in Europe may mean the drug becomes available sooner in your country, though availability timelines vary by nation.
Drug approvalRSSApr 28
A European health committee has recommended that Agamree, a medicine for Duchenne muscular dystrophy (DMD), be approved for use in younger children starting at age 2. Previously, the drug was approved for older children and adults. This recommendation means more DMD patients in Europe could potentially access this treatment if the European Medicines Agency approves the committee's suggestion.
WHY IT MATTERSThis expanded approval could allow children with DMD as young as age 2 to start Agamree treatment earlier, potentially slowing muscle weakness progression during critical early development years.